View in EDS

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.

Saved in:
Bibliographic Details
Title: Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
Authors: Gettinger SN; Yale Cancer Center, Yale-New Haven Hospital, New Haven, Connecticut., Huber RM; Thoracic Oncology Centre Munich, University Hospital of Munich, member of the German Center for Lung Research (DZL, CPC-M), Munich, Germany., Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea., Bazhenova L; University of California San Diego Moores Cancer Center, La Jolla, California., Hansen KH; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark., Tiseo M; Department of Medicine and Surgery, University of Parma, Parma, Italy., Langer CJ; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania., Paz-Ares Rodríguez LG; Medical Oncology Department, Hospital Universitario, Madrid, Spain., West HL; City of Hope Comprehensive Cancer Center, Duarte, California., Reckamp KL; City of Hope Comprehensive Cancer Center, Duarte, California.; Current Affiliation: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California., Weiss GJ; MiRanostics Consulting, Oro Valley, Arizona., Smit EF; Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hochmair MJ; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austria., Kim SW; Department of Oncology, Asan Medical Center, Seoul, South Korea., Ahn MJ; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim ES; City of Hope Comprehensive Cancer Center, Duarte, California., Groen HJM; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands., Pye J; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts., Liu Y; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts., Zhang P; Clinical Science, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado., Vranceanu F; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Clinical Science, Takeda Development Center Americas, Inc., Lexington, Massachusetts., Camidge DR; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2022 Jul 31; Vol. 3 (9), pp. 100385. Date of Electronic Publication: 2022 Jul 31 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36065449
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gettinger+SN%22">Gettinger SN</searchLink>; Yale Cancer Center, Yale-New Haven Hospital, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Huber+RM%22">Huber RM</searchLink>; Thoracic Oncology Centre Munich, University Hospital of Munich, member of the German Center for Lung Research (DZL, CPC-M), Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kim+DW%22">Kim DW</searchLink>; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Bazhenova+L%22">Bazhenova L</searchLink>; University of California San Diego Moores Cancer Center, La Jolla, California.<br /><searchLink fieldCode="AU" term="%22Hansen+KH%22">Hansen KH</searchLink>; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark.<br /><searchLink fieldCode="AU" term="%22Tiseo+M%22">Tiseo M</searchLink>; Department of Medicine and Surgery, University of Parma, Parma, Italy.<br /><searchLink fieldCode="AU" term="%22Langer+CJ%22">Langer CJ</searchLink>; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Paz-Ares+Rodríguez+LG%22">Paz-Ares Rodríguez LG</searchLink>; Medical Oncology Department, Hospital Universitario, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22West+HL%22">West HL</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, California.<br /><searchLink fieldCode="AU" term="%22Reckamp+KL%22">Reckamp KL</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, California.; Current Affiliation: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Weiss+GJ%22">Weiss GJ</searchLink>; MiRanostics Consulting, Oro Valley, Arizona.<br /><searchLink fieldCode="AU" term="%22Smit+EF%22">Smit EF</searchLink>; Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hochmair+MJ%22">Hochmair MJ</searchLink>; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Kim+SW%22">Kim SW</searchLink>; Department of Oncology, Asan Medical Center, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Ahn+MJ%22">Ahn MJ</searchLink>; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+ES%22">Kim ES</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, California.<br /><searchLink fieldCode="AU" term="%22Groen+HJM%22">Groen HJM</searchLink>; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pye+J%22">Pye J</searchLink>; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Zhang+P%22">Zhang P</searchLink>; Clinical Science, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Vranceanu+F%22">Vranceanu F</searchLink>; Oncology Statistics, Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Clinical Science, Takeda Development Center Americas, Inc., Lexington, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Camidge+DR%22">Camidge DR</searchLink>; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2022 Jul 31; Vol. 3 (9), pp. 100385. <i>Date of Electronic Publication: </i>2022 Jul 31 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36065449
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2022.100385
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100385
    Titles:
      – TitleFull: Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gettinger SN
      – PersonEntity:
          Name:
            NameFull: Huber RM
      – PersonEntity:
          Name:
            NameFull: Kim DW
      – PersonEntity:
          Name:
            NameFull: Bazhenova L
      – PersonEntity:
          Name:
            NameFull: Hansen KH
      – PersonEntity:
          Name:
            NameFull: Tiseo M
      – PersonEntity:
          Name:
            NameFull: Langer CJ
      – PersonEntity:
          Name:
            NameFull: Paz-Ares Rodríguez LG
      – PersonEntity:
          Name:
            NameFull: West HL
      – PersonEntity:
          Name:
            NameFull: Reckamp KL
      – PersonEntity:
          Name:
            NameFull: Weiss GJ
      – PersonEntity:
          Name:
            NameFull: Smit EF
      – PersonEntity:
          Name:
            NameFull: Hochmair MJ
      – PersonEntity:
          Name:
            NameFull: Kim SW
      – PersonEntity:
          Name:
            NameFull: Ahn MJ
      – PersonEntity:
          Name:
            NameFull: Kim ES
      – PersonEntity:
          Name:
            NameFull: Groen HJM
      – PersonEntity:
          Name:
            NameFull: Pye J
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Zhang P
      – PersonEntity:
          Name:
            NameFull: Vranceanu F
      – PersonEntity:
          Name:
            NameFull: Camidge DR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 07
              Text: 2022 Jul 31
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1